Risks

High net debt and sub-2x interest coverage leave BHC more exposed than many large-cap healthcare peers to refinancing pressure and covenant sensitivity if rates stay elevated.

A 196-day cash conversion cycle, driven by long inventory and receivables days, ties up working capital and can constrain liquidity versus faster-turning pharma and medtech peers.

Current and quick ratios above 1.0 provide near-term coverage, but they remain only modest buffers relative to stronger balance-sheet peers with lower leverage and better cash generation.

Weak free-cash-flow visibility versus diversified healthcare peers increases dependence on operational improvement and asset sales, which can delay deleveraging and limit strategic flexibility.

Opportunities

BHC’s scale in eye health, surgical, and branded pharmaceuticals supports pricing and channel access that can outperform smaller specialty peers if demand remains stable.

A large inventory base can support service levels and product availability, creating a relative advantage versus peers that face tighter supply or narrower product breadth.

If working-capital efficiency improves, cash release could be meaningful because BHC’s long receivables and inventory cycle offers more upside than peers with already leaner operations.

The company’s broad healthcare exposure provides multiple end-market recovery levers, which can diversify growth versus more concentrated peers if elective demand normalizes.

Overall Score

BHC’s forward positioning is constrained by elevated leverage and weak cash conversion, while scale and portfolio breadth offer some peer-relative upside if working capital and demand improve.